Patient-assessed Late Toxicity Rates and Principal Component Analysis After Image-guided Radiation Therapy for Prostate Cancer
Overview
Authors
Affiliations
Purpose: The aims of this study were to determine the incidence of patient-assessed late toxicity after high-dose, image-guided radiation therapy in a cohort of men with prostate cancer; and to correlate toxicity with conventional dosimetric parameters and rectal and bladder dose-volume histograms (DVH) reduced using principal component analysis.
Methods And Materials: Toxicity questionnaires were sent to 690 men treated for localized prostate cancer to 75.6 Gy or 79.8 Gy using three-dimensional conformal radiation therapy (3DCRT) or intensity-modulated radiation therapy (IMRT) between 1997 and 2003 at the Princess Margaret Hospital. Toxicity was graded according to the modified Radiation Therapy Oncology Group (RTOG)-late effects normal tissue (LENT) scoring system. Late rectal and bladder toxicity scores were dichotomized as < Grade 2 and > or = Grade 2, and correlated with dosimetric parameters and with the first three principal components of rectal and bladder DVHs.
Results: In all, 63% of the patients completed the questionnaire. At a median follow-up of 37 months, the incidence of late rectal toxicity RTOG Grades 1, 2, and 3 was 25.2%, 2.5%, and 0.7% respectively. The incidence of late urinary toxicity RTOG Grade 1, 2, and 3 was 16.5%, 8.8%, and 0.9% respectively. Maintenance of erectile function sufficient for intercourse was reported in 68%. No dosimetric parameter analyzed, including principal component analysis reduction of DVHs, correlated with late toxicity.
Conclusions: Postal questionnaire was effective for collection of patient-assessed late toxicity data. The incidence of late toxicity was low, with a lack of correlation to dosimetric parameters. We attribute this to the use of conformal techniques and daily image guidance.
Clinical Assessment of a Novel Ring Gantry Linear Accelerator-Mounted Helical Fan-Beam kVCT System.
Velten C, Goddard L, Jeong K, Garg M, Tome W Adv Radiat Oncol. 2022; 7(2):100862.
PMID: 35036634 PMC: 8749200. DOI: 10.1016/j.adro.2021.100862.
Houben J, McColl G, Ham Kaanders J, Smeenk R Clin Transl Radiat Oncol. 2021; 29:40-46.
PMID: 34113724 PMC: 8170415. DOI: 10.1016/j.ctro.2021.05.005.
Bian K, Zhou M, Hu F, Lai W Front Genet. 2020; 11:566057.
PMID: 33033496 PMC: 7510777. DOI: 10.3389/fgene.2020.566057.
Vivekanandan S, Landau D, Counsell N, Warren D, Khwanda A, Rosen S Int J Radiat Oncol Biol Phys. 2017; 99(1):51-60.
PMID: 28816160 PMC: 5554783. DOI: 10.1016/j.ijrobp.2017.04.026.
Zapatero A, Roch M, Buchser D, Castro P, Fernandez-Banda L, Pozo G Clin Transl Oncol. 2017; 19(9):1161-1167.
PMID: 28374321 DOI: 10.1007/s12094-017-1655-9.